.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Daiichi Sankyo
Moodys
Covington
Harvard Business School
Dow
AstraZeneca
Cipla
Chubb
Mallinckrodt

Generated: November 19, 2017

DrugPatentWatch Database Preview

DALVANCE Drug Profile

« Back to Dashboard

Which patents cover Dalvance, and when can generic versions of Dalvance launch?

Dalvance is a drug marketed by Allergan Sales Llc and is included in one NDA. There are four patents protecting this drug.

This drug has fifty-three patent family members in sixteen countries.

The generic ingredient in DALVANCE is dalbavancin hydrochloride. One supplier is listed for this compound. Additional details are available on the dalbavancin hydrochloride profile page.

Summary for DALVANCE

US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 2
Drug Prices:see details
DailyMed Link:DALVANCE at DailyMed

Pharmacology for DALVANCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc
DALVANCE
dalbavancin hydrochloride
POWDER;IV (INFUSION)021883-001May 23, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan Sales Llc
DALVANCE
dalbavancin hydrochloride
POWDER;IV (INFUSION)021883-001May 23, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Allergan Sales Llc
DALVANCE
dalbavancin hydrochloride
POWDER;IV (INFUSION)021883-001May 23, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan Sales Llc
DALVANCE
dalbavancin hydrochloride
POWDER;IV (INFUSION)021883-001May 23, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan Sales Llc
DALVANCE
dalbavancin hydrochloride
POWDER;IV (INFUSION)021883-001May 23, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan Sales Llc
DALVANCE
dalbavancin hydrochloride
POWDER;IV (INFUSION)021883-001May 23, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Allergan Sales Llc
DALVANCE
dalbavancin hydrochloride
POWDER;IV (INFUSION)021883-001May 23, 2014RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: DALVANCE

Country Document Number Estimated Expiration
Russian Federation2006136736► Subscribe
Russian Federation2008142899► Subscribe
Australia2003299561► Subscribe
South Korea20120056310► Subscribe
MexicoPA05005338► Subscribe
South Korea20080048093► Subscribe
Hong Kong1114014► Subscribe
South Africa200607888► Subscribe
European Patent Office1565201► Subscribe
Japan5207734► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
US Department of Justice
Merck
Moodys
UBS
Chinese Patent Office
Fish and Richardson
Medtronic
McKesson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot